CBD & Hemp
Extremely narrow 2013 legalisation limited to sub-0.2% THC products. No practical patient access.
Romania passed a narrow medical cannabis law in 2013 permitting only products with up to 0.2% THC. A 2019 draft law expanding access was rejected by parliament. No licences for cultivation, manufacture, import, or export have been granted. Further regulatory development is required before any practical activity is possible.
In 2013, Romania passed an extremely narrow medical cannabis law allowing the use of cannabis derivatives with up to 0.2% THC in medical treatment.
The 2013 law also theoretically permitted cultivation, manufacture, import, and export under licence, but no such licences have ever been granted for medical cannabis.
In 2019, a draft law expanding medical cannabis access and further regulating its commercial activity was adopted by parliament but ultimately rejected by parliamentary vote.
Further regulatory development is required before medical cannabis treatment or production becomes a practical reality in Romania.
Patient access: Extremely limited. The 0.2% THC cap makes practical medical cannabis treatment nearly impossible.
No prescribing pathway or approved product framework exists in practice.
Reimbursement: No framework exists.
No medical cannabis products are available on the Romanian market under the current regulatory framework.
The 0.2% THC ceiling effectively excludes all meaningful THC-based medical cannabis formulations.
No licences for cultivation, manufacture, import, or export of medical cannabis have been granted in Romania.
Commercial cannabis activity is not possible under the current regulatory environment.